Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.41 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046882 | 1.00 | GPBAR1 (0.41) | GPBAR1SLC10A1HSD11B1 | |
| SCHEMBL13420644 | 1.00 | GPBAR1 (0.41) | GPBAR1SLC10A1HSD11B1 | |
| SCHEMBL13420373 | 0.88 | HSD11B1 (0.43) | GPBAR1SLC10A1HSD11B1 | |
| SCHEMBL13420797 | 0.88 | HSD11B1 (0.43) | GPBAR1SLC10A1HSD11B1 | |
| SCHEMBL14047197 | 0.88 | HSD11B1 (0.43) | GPBAR1SLC10A1HSD11B1 | |
| SCHEMBL13420651 | 0.88 | HSD11B1 (0.43) | GPBAR1SLC10A1HSD11B1 | |
| SCHEMBL13642452 | 0.86 | GPBAR1 (0.35) | GPBAR1 | |
| SCHEMBL13642516 | 0.86 | GPBAR1 (0.35) | GPBAR1 | |
| SCHEMBL13420650 | 0.83 | HSD11B1 (0.42) | GPBAR1SLC10A1HSD11B1 | |
| SCHEMBL13420371 | 0.83 | HSD11B1 (0.42) | GPBAR1SLC10A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056487-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | SATORI PHARMACEUTICALS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2008130449-A2 | MODULATORS OF AMYLOID-BETA PRODUCTION | SATORI PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056487-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | APP, BACE1, BACE2 | GPBAR1 1058/4885SLC10A1 902/4885HSD11B1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.